PeerVoice Clinical Pharmacology Audio

Eva Diehl - Wiesenecker, MD - Rare Causes of Abdominal Pain: Differential Diagnosis of Uncommon but Diagnosable Causes in the Emergency Room

Alberto Ortiz, MD, PhD - Rare, Complex, and Life-Threatening: Recognizing and Responding to Atypical Hemolytic Uremic Syndrome

Thanai Pongdee, MD - From Diagnosis to Treatment Escalation: Improving Outcomes Across the Patient Journey in Indolent Systemic Mastocytosis

Jonathan Barratt, PhD, FRCP - The Nephrology Journal Club: B-Cell Modulators and eGFR Endpoints in IgA Nephropathy

Neal Shore, MD, FACS - Redefining Expectations in mHSPC: Options and Opportunities Across the Spectrum of Disease

Howard Trachtman, MD - Pioneering Progress In Focal Segmental Glomerulosclerosis: Time is Ticking To Save The Nephron

Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?

Lorenza Rimassa, MD - Shifting the Paradigm in Biliary Tract Cancers: Contemporary Data and Decision-Making

Diana L. Bitner, MD, MSCP, FACOG - Let's Replace Silence With Science: Patient and Provider Perspectives on Addressing the Substantial Impact of Menopausal Symptoms

Angela Kay Fitch, MD, FACP, MFOMA - Separating Signal From Noise: Overcoming the Challenges of Obesity Management in Real-World Clinical Practice

Saiju Jacob, MD, DPhil, FRCP, FAAN - The Value of Disease Control in gMG: The Latest Data Evaluating Patient Needs and Treatment Outcomes as They Emerge From Helsinki

Liz Lightstone, MBBS (Hons), PhD, FRCP - Preventing Flare and Protecting Function: What Progress Is Being Made in Active Lupus Nephritis?

Anna Maria Geretti, MD, PhD - Understanding an Individual's Readiness for Long-Acting Injectable Therapy

Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges

Maria Dall'Era, MD - When They Need Targeted Therapy: Selecting the Optimal Treatment Approach for Lupus Nephritis in an Evolving Treatment Landscape

Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer

Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed

Mike Sharma, MD, MSc, FRCPC - Can We Set a New Standard of Care for Secondary Stroke Prevention? Evaluating Current Gaps and Future Goals

Enrico Lopriore, MD, PhD - Are You Managing Pregnant Individuals? Then You Need to Know About Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT)

Mariana Castells, MD, PhD - Rare But Highly Significant: Best Practices in Recognizing and Diagnosing Systemic Mastocytosis

Olivier Bonnot, MD, PhD - Acute Psychosis: When to Suspect Acute Hepatic Porphyria

Darren M. Brenner / Benoît Coffin - If I'd Known Then What I Know Now: Recognising My First AHP Patient

Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC

Olga Kordonouri, MD - Confronting the Silent Progression of Type 1 Diabetes: Rationales and Roadmaps for Early Detection and Proactive Intervention

Kris V. Kowdley, MD - Prioritising the Patient Experience With PBC: Are We Appreciating and Addressing the True Impact of the Disease?

Pushpa Narayanaswami, MD, FAAN - Cutting Through the Congress Cacophony on Generalised Myasthenia Gravis: Expert Honing of the Latest Data

Erika Hamilton, MD - Safety First: Recognising and Responding to Toxicities Associated With TROP2-Directed Therapies in Metastatic Breast Cancer

Onyema Ogbuagu, MD, FACP, FIDSA - Multidrug-Resistant HIV: Evaluating HIV Treatment Strategies as Options Narrow

Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours

Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML

Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice

Neal Shore, MD, FAC - Advancing Care for mCRPC With Life-Prolonging Therapies: Existing and Emerging Roles for Radiopharmaceuticals

Angela Fitch, MD, FACP, MFOMA - This Cannot Weight: A Specialist Guide to Weight Management and Obesity Associated With Emotional Eating Behaviours

Bruce A C Cree, MD, PhD, MAS - BTK Inhibition & Beyond: Novel Therapies in MS

Elena Castro, MD, PhD - Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences

Karin Jordan, MD, PhD - Applying Foresight to Optimise Emesis Control in Patients Receiving Antibody-Drug Conjugates

Karin Jordan, MD, PhD - Practical Protocols for Preventing and Managing Antibody-Drug Conjugate-Associated Nausea and Vomiting

Deborah Siegal, MD, MSc, FRCPC / Richard Body, MBChB, FRCEM, PhD - Turn the Bleed Around: Expert Perspectives on the Evolving Evidence for Management of Factor Xa Inhibitor-Associated Life-Threatening Bleeding

Jiwon Oh, MD, PhD, FRCPC - Navigating the High-Efficacy DMT Landscape in MS: Integrating New Data and Real-World Evidence

Frank Siebenhaar, PD / Vito Sabato, MD, PhD - Optimising Outcomes in Indolent Systemic Mastocytosis: A Comprehensive Review of Best Practices Across the Patient Journey